NEW YORK, NY--(Marketwire -01\/31\/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN - News) and ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.fivestarequities.com\/DNDN<\/a> Gunderson Capital Management argues that part of biotech's rally is being driven by expectations that President Barack Obama's health care reform plan may be repealed. Earlier this month House Republicans pushed through a resolution in support of a Constitutional amendment that would repeal Obamacare. House Resolution 1003 asks Congress to call a constitutional convention to propose an amendment to repeal the Affordable Care Act, which is also set to be challenged before the Supreme Court this year. <\/p>\n Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.fivestarequities.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n ADVENTRX's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. In December ADVENTRX met with the U.S. Food and Drug Administration (FDA) to review development plans for ANX-188. <\/p>\n Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.fivestarequities.com\/disclaimer<\/a> <\/p>\n<\/p>\n Follow this link: NEW YORK, NY--(Marketwire -01\/31\/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Continue reading
http:\/\/www.fivestarequities.com\/ANX<\/a> <\/p>\n
\nBiotech Sector on the Upswing -- Dendreon and ADVENTRX Pharmaceuticals Looking Strong<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"